LS60 Stock Chart & Stats
€0.13
<€0.01(3.23%)
At close: 4:00 PM EDT
€0.13
<€0.01(3.23%)
Day’s Range― - ―
52-Week Range€0.12 - €1.16
Previous CloseN/A
Volume0.00
Average Volume (3M)75.00
Market Cap
€5.55M
Enterprise Value€100.00
Total Cash (Recent Filing)€13.04M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.01
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding31,163,593
10 Day Avg. Volume175
30 Day Avg. Volume75
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.55
Price to Sales (P/S)10.18
P/FCF Ratio-4.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€2.83M
Bulls Say, Bears Say
Bulls Say
Installed‑base Recurring RevenueCLS's commercial model pairs capital equipment sales with recurring disposables, software and service revenue. That installed-base dynamic supports durable revenue streams and higher lifetime customer value if system placements scale, cushioning growth volatility over months.
Niche, Image‑guided Lasertherapy PlatformCLS offers a differentiated medical-technology platform combining laser ablation with imaging guidance. Structural industry trends toward minimally invasive, image-guided procedures give the company a durable competitive niche that can drive adoption and procedure-level economics over the medium term.
Very Low Leverage / Equity CushionA debt-free balance sheet and meaningful equity cushion reduce financial fragility, lower bankruptcy risk, and give management flexibility to fund commercialization or R&D. This structural capital strength improves runway options despite operational losses.
Bears Say
Shrinking RevenueDeclining top-line reduces the company’s ability to leverage installed-base dynamics and scale recurring consumable and service sales. Over 2–6 months a falling revenue trend can indicate weak adoption, reduced procedure volumes, or commercial execution shortfalls that hinder path to profitability.
Negative Gross And Operating MarginsPersistently negative gross margins imply product or cost-structure issues that margin expansion alone may not fix. Deeply negative operating/net margins mean the business currently cannot cover fixed costs; without structural margin improvement, scaling revenue will not translate into sustainable profits.
Sustained Cash BurnNegative free cash flow of roughly -34.8M TTM indicates the company is consuming cash to operate and grow. Even with zero debt, ongoing burn limits runway and forces reliance on external funding or dilution unless operational performance and cash conversion improve materially.
LS60 FAQ
What was Clinical Laserthermia Systems AB Class B’s price range in the past 12 months?
Clinical Laserthermia Systems AB Class B lowest stock price was €0.12 and its highest was €1.16 in the past 12 months.
What is Clinical Laserthermia Systems AB Class B’s market cap?
Clinical Laserthermia Systems AB Class B’s market cap is €5.55M.
When is Clinical Laserthermia Systems AB Class B’s upcoming earnings report date?
Clinical Laserthermia Systems AB Class B’s upcoming earnings report date is Nov 13, 2026 which is in 106 days.
How were Clinical Laserthermia Systems AB Class B’s earnings last quarter?
Clinical Laserthermia Systems AB Class B released its earnings results on Jul 17, 2026. The company reported -€0.035 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Clinical Laserthermia Systems AB Class B overvalued?
According to Wall Street analysts Clinical Laserthermia Systems AB Class B’s price is currently Overvalued.
Does Clinical Laserthermia Systems AB Class B pay dividends?
Clinical Laserthermia Systems AB Class B does not currently pay dividends.
What is Clinical Laserthermia Systems AB Class B’s EPS estimate?
Clinical Laserthermia Systems AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinical Laserthermia Systems AB Class B have?
Clinical Laserthermia Systems AB Class B has 31,163,593 shares outstanding.
What happened to Clinical Laserthermia Systems AB Class B’s price movement after its last earnings report?
Clinical Laserthermia Systems AB Class B reported an EPS of -€0.035 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.689%.
Which hedge fund is a major shareholder of Clinical Laserthermia Systems AB Class B?
Currently, no hedge funds are holding shares in DE:LS60
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinical Laserthermia Systems AB Class B
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. The company also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers that provides multiple options to control treatment. In addition, it offers various gauge laser applicators and introducers, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
Technical Analysis
SpectraCure AB
―
Luxbright AB
―
Scandinavian Real Heart AB
―
Nosa Plugs AB
―
Arcoma AB
―